Exploring potential mediators of the cardiovascular benefit of dulaglutide in type 2 diabetes patients in REWIND

Exploring potential mediators of the cardiovascular benefit of dulaglutide in type 2 diabetes patients in REWIND

Abstract Background The REWIND trial demonstrated cardiovascular (CV) benefits to patients with type 2 diabetes and multiple CV risk factors or established CV disease. This exploratory analysis evaluated the degree to which the effect of dulaglutide on CV risk factors could statistically account for...

Full description

Bibliographic Details
Main Authors: Manige Konig, Matthew C. Riddle, Helen M. Colhoun, Kelley R. Branch, Charles M. Atisso, Mark C. Lakshmanan, Reema Mody, Sohini Raha, Hertzel C. Gerstein
Format: Article
Language:English
Published: BMC 2021-09-01
Series:Cardiovascular Diabetology
Subjects:
Cardiovascular
Diabetes
Dulaglutide
Glucagon-like peptide-1
Mediators
Online Access:https://doi.org/10.1186/s12933-021-01386-4

Internet

https://doi.org/10.1186/s12933-021-01386-4

Similar Items